Pharmaceutical Technology
MARCH 9, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: In-vitro T-cell activation. Immatics is the leading patent filer in in-vitro T-cell activation.
pharmaphorum
FEBRUARY 19, 2021
Snipping out this viral code with powerful CRISPR gene editing technology, which last year won Drs Emmanuelle Charpentier and Jennifer Doudna the Nobel Prize for chemistry, would in theory prevent the need for drugs to suppress the virus and the development of AIDS.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 12, 2023
The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . What are organoids? .
pharmaphorum
NOVEMBER 1, 2022
In 2023 we will see the return of SAE’s RNA Therapeutics conference to a live in-person event, showcasing an update on mRNA therapeutic applications, coupled with an industry outlook of the field. We will also explore the latest trends in novel RNA therapies, including developments in AI modelling and small molecule modulation of RNA.
Drug Discovery World
JULY 3, 2023
This was centred around pre-clinical models (in vitro and in vivo) to support discovery and development, re-entering the fray with costimulatory agonists, and clinical development strategies for combinations with immune cell engagers.
Drug Discovery World
JULY 10, 2023
For projects that utilise gene targeting in ESCs, founders are chimeric (composed of genetically distinct cells derived from two different sources: modified ESCs and a host blastocyst). Yet when seeking to obtain an existing model, researchers often encounter obstacles related to intellectual property, availability, or licensing.
Drug Discovery World
DECEMBER 13, 2022
One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene. Using an experimental technique called exon skipping by antisense oligonucleotides, the team corrected a mistake in the FKTN gene that blocks the chemical glycosylation of a biologically important protein. . Modifying RNA function.
Expert insights. Personalized for you.
130 
Let's personalize your content